GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSN) » Definitions » Price-to-Tangible-Book

NeuroSense Therapeutics (NeuroSense Therapeutics) Price-to-Tangible-Book : (As of Jun. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Price-to-Tangible-Book?

As of today (2024-06-05), NeuroSense Therapeutics's share price is $1.17. NeuroSense Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $-0.12. Hence, NeuroSense Therapeutics's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for NeuroSense Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

During the past 5 years, NeuroSense Therapeutics's highest Price to Tangible Book Ratio was 2.99. The lowest was 2.56. And the median was 2.78.

NRSN's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.78
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, NeuroSense Therapeutics's share price is $1.17. NeuroSense Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $-0.12. Hence, NeuroSense Therapeutics's P/B Ratio of today is .


NeuroSense Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for NeuroSense Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics Price-to-Tangible-Book Chart

NeuroSense Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
- - 2.99 2.56 -

NeuroSense Therapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.56 7.02 - - -

Competitive Comparison of NeuroSense Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, NeuroSense Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroSense Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroSense Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where NeuroSense Therapeutics's Price-to-Tangible-Book falls into.



NeuroSense Therapeutics Price-to-Tangible-Book Calculation

NeuroSense Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=1.17/-0.122
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


NeuroSense Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroSense Therapeutics (NeuroSense Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11 HaMenofim Street, Building B, Herzliya, ISR, 4676670
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.